Please wait while the transcript is being prepared...
I'm Edith Sim.
I'm going to be talking about a family
of drug metabolizing enzymes.
And I have been working on this family of enzymes
for more than 20 years.
And this represents an update
on what was presented previously
in a former version of a Henry Stewart talk.
As a code, slides with an "S" in the upper left hand corner
contain advanced supplementary information
in addition to the core material which is presented
throughout the talk.
are cytosolic enzymes
which are commonly called phase II drug metabolizing enzymes.
They're around 30-34 kDa in size,
and are widespread amongst eukaryotes and prokaryotes.
They were first recognized
for their role in the N-acetylation
of hydrazines and arylamines.
At the end of the first edition of the Henry Stewart talk,
I suggested that the future
would be the 3D structure of NAT from mammals,
and the effects of mutation on activity.
And I ask the question:
"Whether NAT has a rule in addition
to drug metabolizing enzymatic activity?"
In this talk, next, I'm going to identify to what extent the future is here.
And the answer is that
most of these future ideas will be covered
in the current talk.
The overview of the talk that I am going to give today is: